middle.news
Dimerix builds cash buffer as second kidney drug moves toward trials
8:31am on Thursday 29th of October, 2026 AEDT
•
Biotechnology
Read Story
Dimerix builds cash buffer as second kidney drug moves toward trials
8:31am on Thursday 29th of October, 2026 AEDT
Key Points
A$14.1 million Everest Medicines upfront payment received
Cash rose to A$34.8 million at 30 September 2026
A$16.7 million drawn from a A$34 million secured facility
ACTION3 Phase 3 remains fully recruited with 333 patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE